Reckitt Benckiser Group PLC (OTCMKTS:RBGLY – Get Free Report) passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $13.42 and traded as low as $12.95. Reckitt Benckiser Group shares last traded at $13.08, with a volume of 319,114 shares changing hands.
Analyst Ratings Changes
A number of equities analysts have issued reports on RBGLY shares. Jefferies Financial Group raised Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a report on Tuesday, July 21st. Zacks Research upgraded Reckitt Benckiser Group from a “strong sell” rating to a “hold” rating in a report on Friday, August 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Reckitt Benckiser Group in a research note on Tuesday, June 30th. Finally, BNP Paribas Exane downgraded shares of Reckitt Benckiser Group from an “outperform” rating to a “neutral” rating in a research report on Wednesday, September 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Reckitt Benckiser Group presently has a consensus rating of “Moderate Buy”.
Get Our Latest Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Price Performance
About Reckitt Benckiser Group
Reckitt Benckiser Group plc, now known as Reckitt, is a United Kingdom-based consumer health and hygiene company headquartered in Slough, England. The company develops, manufactures and markets products intended to support personal health, household cleanliness and hygiene.
Its brand portfolio includes consumer health products such as Nurofen, Strepsils, Mucinex and Durex, as well as household and hygiene brands including Dettol, Lysol, Finish and Vanish. Reckitt’s products are sold through retailers, pharmacies, e-commerce platforms and other distribution channels.
The company was formed in 1999 through the merger of Reckitt & Colman and Benckiser.
Further Reading
- Five stocks we like better than Reckitt Benckiser Group
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.
